Nathan A Ledeboer joins the Scientific Advisory Board at Gradientech
The diagnostics company Gradientech today announces that Dr Nathan A. Ledeboer, specialist within the Froedtert & Medical College of Wisconsin network, joins as new member of the company’s prominent international Scientific Advisory Board.
Dr Ledeboer is Professor and Chief of Clinical Pathology in the Department of Pathology and Laboratory Medicine at the Medical College of Wisconsin, USA. He served as the Medical Director of Microbiology and Molecular Diagnostics for Froedtert Hospital and Wisconsin Diagnostic Laboratories in Milwaukee, WI for 16 years before assuming the role of Associate Chief Medical Laboratory Officer for Froedtert Health. His research, focused on developing diagnostic tools for infectious diseases to improve patient care and hospital epidemiology, has been recognised in more than 130 publications exceeding 4,000 citations.
“We are honoured to welcome Nate Ledeboer to our Scientific Advisory Board. Nate is a highly respected and well-known key opinion leader within the field of clinical microbiology, including antibiotic susceptibility testing,” says Sara Thorslund, co-founder and CEO at Gradientech. “With hands-on experience with the QuickMIC® system from our pre-clinical studies together with the Medical College of Wisconsin last year, Nate will contribute significantly to our scientific and clinical discussions.”
“I am excited to join the Scientific Advisory Board for Gradientech. Despite many advances in the practice of clinical microbiology, most clinical microbiology laboratories continue to use antimicrobial susceptibility testing systems with turnaround between 10 and 24 hours. We continue to need accurate susceptibility information that can be delivered much earlier in the patient’s treatment course”, says Nathan Ledeboer, new member of the Scientific Advisory Board at Gradientech.
The QuickMIC system's ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance on the right antibiotic in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 (0)736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden.
Visit www.gradientech.se for more information.
